The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis

BACKGROUND: Teriflunomide is a first-line oral immunomodulatory agent approved in China for the treatment of relapsing multiple sclerosis. OBJECTIVE: To compare the treatment outcomes of teriflunomide and no disease-modifying therapy (DMT) treatment (in first year) in multi-center real-world Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Bitao, Quan, Chao, Li, Wenyu, Zeng, Qiuming, Shi, Ziyan, Chen, Bo, Zhou, Lei, Jin, Luya, Zhou, Hongyu, Yang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387708/
https://www.ncbi.nlm.nih.gov/pubmed/37529720
http://dx.doi.org/10.1177/17562864231181170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387708/
https://www.ncbi.nlm.nih.gov/pubmed/37529720
http://dx.doi.org/10.1177/17562864231181170

Ejemplares similares